Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.

"Competing interests RCB receives royalties from Fujirebio Diagnostics Inc. for the discovery of CA125. Massachusetts General Hospital has co-licensed software for ROCA to Abcodia, now owned by GenInCode, with MGH license revenue to MGH and research laboratories per MGH institutional policies."

"This project was supported by grants from the National Cancer Institute Early Detection Research Network U01 CA200462 (RCB), 5 U01 CA152990 and U2C CA271871(S.J.S), U01 CA117374 (KSA), the MD Anderson Ovarian SPOREs P50 CA83639 and P50CA217685 (RCB) and R01 CA247220 (AEL and RCB), National Cancer Institute, Department of Health and Human Services; the Cancer Prevention Research Institute of Texas (RP160145) (RCB); Minnesota Ovarian Cancer Alliance (RCB), Golfer’s Against Cancer, the Mossy Foundation, the Anne and Henry Zarrow Foundation, the Roberson Endowment, National Foundation for Cancer Research, UT MD Anderson Women’s Moon Shot, and generous donations from Stuart and Gaye Lynn Zarrow, Karen and Barry Elson, Arthur and Sandra Williams and the Concord (MA) Detect Ovarian Cancer Early Fund. We gratefully acknowledge provision of TP53 autoantibody assay kits (EVAL-5) from Roche Diagnostics, Inc."